Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 24Leukemia, Myeloid, Acute 16Myeloproliferative Disorders 15Polycythemia Vera 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 9Thrombocythemia, Essential 8Graft vs Host Disease 8Recurrence 6Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Dasatinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × ruxolitinib × 1 year × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡